Beyond NUPCO: How Saudi Arabia's Institutional Buyers Actually Purchase

Most market-entry guides describe Saudi Arabia as one buyer: register with SFDA, qualify with NUPCO, win a tender. That picture is incomplete. The Kingdom's health system has several institutional buyers with their own budgets, their own supplier registration, and their own way of deciding. A manufacturer who understands the map can choose where to start, and that choice often determines whether the first year produces orders or only meetings.

1. The map

Government spending accounts for the majority of Saudi healthcare expenditure, and the public system is in the middle of a structural transformation under Vision 2030. For a supplier, the institutions fall into five groups.

Ministry of Health hospitals and the health clusters. The largest network in the country, now being reorganised into regional health clusters under the Health Holding Company. The great majority of their pharmaceuticals, devices, and supplies are procured centrally through NUPCO frameworks and tenders. This is the channel most guides describe, and it is covered in our NUPCO article.

Specialist and reference institutions with independent budgets. A small number of large, highly specialised centres run their own procurement, maintain their own supplier registration, and issue their own tenders and purchase orders. King Faisal Specialist Hospital & Research Centre (KFSHRC), with its own supplier portal, is the best-known example. These institutions treat complex cases, adopt new technology early, and are watched closely by the rest of the system.

Ministry of National Guard Health Affairs (NGHA). A separate hospital system with its own facilities across the Kingdom, its own procurement function, and its own clinical and academic standing.

Military and security medical services. The Armed Forces medical services and the medical services of other security sectors operate their own hospitals and their own purchasing. They are distinct from the Ministry of Health and from each other.

The private sector. Large hospital groups and standalone private hospitals and clinics, buying on commercial terms, often faster than the public sector and more sensitive to price, brand, and patient demand. The government's stated aim is to grow the private sector's share of provision substantially by 2030.

Each group buys differently. Treating them as one "Saudi market" is the most common strategic error we see.

2. How each channel buys

In every case the supplier of record is a Saudi-licensed entity: a foreign manufacturer sells into these institutions through a distributor or agent that holds the SFDA establishment licence and the relevant registrations. The manufacturer's role is to make the product wanted; the partner's role is to make it purchasable.

3. Why innovative products usually start outside NUPCO

NUPCO frameworks are built around defined categories, standard specifications, and price competition. That suits established product types with several qualified suppliers. It suits a new technology poorly: there may be no category, no specification written for it, and no history of use in the Kingdom.

The specialist institutions, National Guard, and leading private groups are where new technology usually enters. They can evaluate a product clinically, buy it under their own authority, and generate the local experience that later supports a NUPCO listing. A typical sequence for a differentiated device is: clinical evaluation and first purchase at one or two reference institutions; adoption by a private group; and then, with local evidence and demand in hand, inclusion in a NUPCO framework. Manufacturers who begin with NUPCO for such products often spend a year waiting for a category that does not yet exist.

The reverse is also true. A commodity consumable with many competitors will rarely justify the effort of institution-by-institution selling; there, NUPCO frameworks and the right partner are the whole game.

4. Building a clinical champion

Across all the institutional channels, the decisive factor for a new product is a clinician who wants it and is prepared to say so in the evaluation process. Committees are technical, but they are staffed by people who know which products they have seen work.

Building that support is slow, specific work: identifying the departments where the product solves a real problem; arranging evaluations, samples, and training through the licensed partner; providing the clinical evidence in the form the institution expects; and being present when questions arise. It cannot be done from abroad, and it cannot be delegated entirely to a distributor with three hundred other products. This is where a manufacturer's own investment, or a partner on the ground acting for it, makes the difference.

5. Choosing where to start

Three questions usually settle the sequence:

1. Is the product a new category or a better version of an existing one? New categories start with specialist and private institutions; existing categories start with NUPCO and the partner's tender capability.
2. Who is the clinical decision-maker? If a specific specialty drives the purchase, the institutions with the strongest departments in that specialty come first.
3. What can the partner actually reach? A distributor's real access, by institution, matters more than its size. Ask for reference customers by channel before deciding.

The answers produce a short list of two or three institutions to focus on in the first year, rather than a national plan that reaches none of them.

Frequently asked questions

Do I need NUPCO qualification to sell to KFSHRC or National Guard hospitals?

No. These institutions run their own procurement and supplier registration. NUPCO qualification is required for the MOH network it serves.

Can a hospital buy a product that is not yet SFDA-registered?

Registration is the rule. Limited exceptions exist for specific clinical needs under SFDA's own procedures; they are not a substitute for an MDMA and should be discussed with your regulatory partner case by case.

Is the private sector easier than the public sector?

Faster, usually, and more price-driven. Private groups also watch what the leading public institutions adopt, so the two channels reinforce each other.

How long before a new product produces institutional orders?

With a registered product, a capable partner, and a clear target list, first institutional purchases within six to twelve months are realistic. Without a clinical champion, the same product can wait indefinitely.

Related reading: Why Foreign Manufacturers Get Disqualified from NUPCO Tenders · How to Choose a Saudi Distributor

This article describes the general structure of institutional purchasing in Saudi Arabia as of the date above. Each institution's procedures are defined by that institution and may change; confirm current requirements with your licensed Saudi partner before engaging.